Institutional investors purchased a net $2.5 million shares of REGN during the quarter ended March 2014. This may signal that the smart money is gaining interest in this company as the 75.28% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
SWEDBANK ROBUR FONDER AB Bought 27.4 Thousand shares of Regeneron Pharmaceuticals...